are responsible for other sporadic and familial forms of the disease and could lead to the identification of new susceptibility genes.
Several types of protein-protein interaction maps have been developed. These include specific interaction networks, such as the ataxia network presented by Lim et al. (2006) , which generate a huge number of gene modifier candidates that may participate in or regulate pathogenic processes. Other networks have described interactions across the entire proteome in model organisms such as yeast, Drosophila, and Caenorhabditis elegans. Approaches to systematically map human protein interactions have also been undertaken (Rual et al., 2005; Stelzl et al., 2005) . These networks are certainly not independent and should be considered together as they will contribute in a complementary manner to understanding the mechanisms that control cellular behavior in development and disease. Indeed, thousands of interactions have been described, and now the challenge is to conduct comparative analysis of these interactomes to organize these data. We also need to further address the dynamics of these systems. Thus, it will be critical to determine when and where these interactions occur and how they are regulated both within a given cell and in the context of whole tissues. Goehler, H., Lalowski, M., Stelzl, U., Waelter, S., Stroedicke, M., Worm, U., Droege, A., Lindenberg, K.S., Knoblich, M., Haenig, C., et al. (2004) . Mol. Cell 15, 853-865. Lim, J., Hao, T., Shaw, C., Patel, A.J., Szabó, G., Rual, J.-F., Fisk, C.J., Li, N., Smolyar, A., Hill, D.E., et al. (2006) . Cell, this issue.
Rual, J.F., Venkatesan, K., Hao, T., HirozaneKishikawa, T., Dricot, A., Li, N., Berriz, G.F., Gibbons, F.D., Dreze, M., Ayivi-Guedehoussou, N., et al. (2005) Validating therapeutic targets is an inherently difficult undertaking. The sheer number of potential drug targets in the postgenomic era makes validation the rate-limiting step in drug development (Lindsay, 2003) . Not surprisingly, many more therapeutic candidates fail because of a lack of efficacy rather than because of safety concerns. Owing to the astronomical costs of drug development, a high threshold is set for the validation of new drug targets. The ideal drug target is one whose inhibition leads to the desired therapeutic outcome and does not lead to deleterious so-called mechanism-based side effects. Mechanism-based side effects arise from the inhibition of the normal function of an enzyme, which is separate from its disease-associated function. But for any given target, the likelihood of a simple pharmacological landscape with no off-target activity due to inhibition of homologous proteins and no mechanismbased side effects is low. However,
Using Isoform-specific Inhibitors to Target Lipid Kinases
in two recent studies, including one in this issue (Fan et al., 2006; Knight et al., 2006) , Kevan Shokat and colleagues demonstrate that preclinical validation of therapeutic targets can be accomplished with the right set of tools and a thorough understanding of the target's function in a complex biological system.
As targets for drug development, lipid kinases have lagged behind the protein kinases, but this trend may be set to change. Three new studies identifying specific and parallel functions of lipid kinases may open the door to the development of drugs targeting specific phosphoinositide-3′-OH kinase (PI3-K) family members. In this issue, Knight et al. (2006) report a detailed pharmacological analysis of PI3-K isoforms using small molecule inhibitors. In addition, recent publications in Nature (Foukas et al., 2006) and Cancer Cell (Fan et al., 2006) describe advances in understanding PI3-K function and in the development of treatments based on the selective inhibition of PI3-K isoforms.
The mammalian PI3-K family consists of eight catalytic isoforms (Hennessy et al., 2005) . In addition, five genes encode regulatory subunits. More distant family members include the phosphoinositide-4′-OH kinases (PI4-K) and the ATM, ATR, DNA-PK, and mTOR protein kinases. Varied patterns of PI3-K expression, abundance, and subunit composition as well as overlapping and redundant functions have made PI3-Ks difficult to exploit as therapeutic targets. Given this embarrassment of riches, it has been difficult to determine exactly which isoforms uniquely perform specific functions. Gene knockout studies in mice have shed some light on the topic, but all too often, the phenotypes observed in these experiments fall at either extreme and are either very mild (for example, with expression of p110γ with an inactive kinase) or are embryonic lethal (such as knockout of either p110α or p110β) (Vanhaesebroeck et al., 2005) .
Small molecules have several advantages as tools for validating potential therapeutic targets. First and foremost, unlike the validation strategies using RNAi or gene disruption, small molecules can themselves act as drugs. And as allelic replacement studies with p110γ have shown, the absence of a target due to gene disruption may not be equivalent to inhibition of a target (for example, replacement of the gene with an allele encoding an inactive kinase) (Patrucco et al., 2004) . Also, small molecules allow for temporal and incremental control over the activity of the target. Finally, small molecules can be exquisitely specific, inhibiting only one among many related targets, or they can be highly selective, inhibiting a defined subset of targets. In the past, only panselective PI3-K inhibitors such as LY-294002 and the natural product wortmannin have been available for study. This has limited the use of small molecules to validate particular PI3-K isoforms as potential therapeutic targets. Knight et al. (2006) present a detailed interrogation of PI3-K and related kinases using a diverse panel of PI3-K inhibitors. The authors assembled a collection of PI3-K inhibitors based on the literature and on patents granted as well as new compounds synthesized in their laboratories. A panel of 15 kinases was tested using inhibitors from nine distinct chemical classes. One of these compounds was highly selective, such that its IC 50 (the concentration of inhibitor at which the enzyme activity is 50% of its maximum) for the kinase most affected by the compound was 400 times lower than the IC 50 for the second-most sensitive kinase. However, most inhibitors showed a moderate selectivity of 2-to 10-fold. In any case, the panel of compounds used by is of sufficient structural diversity to provide inhibitors that are at least partially selective for each of the p110 isoforms of PI3-K. Using principal component analysis, the authors uncovered a cryptic relationship between p110α and DNA-PK. In spite of limited primary-sequence homology, the two kinases are pharmacological homologs, or pharmalogs, meaning that inhibitors of one kinase usually target the other as well. This type of analysis provides a means to anticipate off-target activity and undesired side effects.
In order to gain insight into the molecular bases for the selectivity of the inhibitors, Knight et al. (2006) determined the cocrystal structures of p110γ bound to three different inhibitors: PIK-39 (selective for p110δ), PIK-90 (selective for p110α), and PIK-93 (selective for p110γ). In addition, structural models were created of p110 bound to PI-103 (selective for DNA-PK), PIK-108 (selective for p110β) and KU-55933 (selective for ATM). These structural studies reveal a delicate balance between affinity and selectivity. Nonselective, high-affinity inhibitors occupy the ATP binding site, rely on similar electrostatic and steric interactions, and access a hydrophobic pocket adjacent to the ATP site. In contrast, highly specific inhibitors (such as PIK-39) rely on a hydrogen bond to the backbone amide of Val882, a core interaction that is shared by all PI3-K inhibitors and ATP, but also have contacts outside of the ATP binding pocket. Specifically, Met804 may act as a selectivity switch that blocks access to a hydrophobic pocket between it and Trp812. Only PIK-39 has an architecture that is sufficiently complementary to induce a conformational rearrangement of Met804 and allow an energetically favorable interaction within the hydrophobic pocket.
It is known that PI3-K plays a key role in insulin signaling by linking the insulin receptor and insulin-receptor substrate (IRS) proteins to downstream effectors (White, 2003) . The nonselective inhibitors wortmannin and LY-294002 are capable of blocking all insulin-induced lipid kinase activity in IRS1 or IRS2 complexes. However, the lack of selectivity for these compounds precludes identification of specific PI3-K isoforms as targets in the insulin signaling cascade. Homozygous deletion of p110α or p110β in mice leads to embryonic lethality, whereas the heterozygotes show no metabolic defects (Brachmann et al., 2005) . A recent publication in Nature (Foukas et al., 2006 ) describes a mouse model in which the activity of p110α is attenuated. Foukas et al. (2006) created a transgenic mouse in which one allele of p110α has no kinase activity and the other is the normal wild-type allele. This mouse shows decreased insulin signaling, glucose intolerance, and increased formation of adipose tissue. Thus, the authors conclude that p110α is the PI3-K isoform required for insulin signaling. Remarkably, using the panel of specific and selective PI3-K inhibitors, Knight et al. (2006) come to the same conclusion. Knight et al. (2006) show that, although multiple isoforms are expressed in adipocytes and myotubes, in both systems, p110α is the primary isoform required for insulin signaling. Interestingly, p110δ and/ or p110γ may provide an additional source of inositide triphosphates in myotubes but not in adipocytes. Inhibition of both p110δ and p110γ has no effect on the ability of the p110α inhibitor PIK-75 to block activation of Akt kinase in adipocytes. In contrast, inhibition of p110δ and p110γ works synergistically with PIK-75 to block the activation of Akt kinase in myotubes.
The PI3-K family is known to promote cell growth and survival and is believed to play a role in cancer. Evidence for the role of PI3-K in cancer has been demonstrated in three ways. First, the PI3-K signal that is stimulated by growth factors is negatively regulated by the dual-specificity phosphatase and tensin homolog (PTEN), which is inactivated through mutation or transcriptional silencing in a significant percentage of sporadic tumors. Second, altered Akt kinase activity, a downstream effector of PI3-K signaling, also occurs in a variety of epithelial and hematopoietic malignancies. Third, mutations or activating translocations in p110α, although rare, have also been documented. Thus, there is much evidence in support of the conclusion that aberrant activation of Akt through PI3-K allows cancer cells to bypass growth-limiting controls (Cully et al., 2006) . Until recently, however, the lack of isoform-specific inhibitors has largely precluded validating PI3-K as a therapeutic target for the treatment of cancer. In a recent paper in Cancer Cell, Fan et al. (2006) used the same diverse collection of PI3-K inhibitors described by Knight et al. (2006) to survey a panel of glioma cell lines. The panselective PI3-K inhibitor LY-294002 blocks Akt phosphorylation and causes cell death at similar concentrations. In contrast, a specific inhibitor of p110α (PI-103) blocks Akt phosphorylation and causes a G0/G1 cell-cycle arrest at a concentration that is 50-fold lower than that required to induce cell death. An inhibitor of the p110β and p110δ isoforms (TGX-286) also blocks Akt phosphorylation but does not induce cell-cycle arrest. On the basis of the pharmacological survey of PI3-K isoforms presented by Knight et al. (2006) , Fan et al. (2006) hypothesized that concurrent inhibition of p110α and mTOR, a unique property of PI-103, was required for growth inhibition. Using a combination of rapamycin, an inhibitor of mTOR, and an inhibitor of p110α that does not target mTOR (PIK-90), the authors showed this to be the case. Moreover, PI-103 inhibits proliferation of glioma cells in vivo. U8MG glioma cells that express an activated form of the epidermal growth-factor receptor were implanted into immunodeficient mice. Tumor-bearing mice received PI-103 or vehicle as a control. The dual-specificity p110α/ mTOR inhibitor blocked tumor growth by preventing Akt phosphorylation and inducing cell-cycle arrest.
The findings that inhibition of p110α (and mTOR) in cancer cells causes growth inhibition and that blocking activation of p110α in adipocytes leads to inhibition of insulin signaling raise an important and troubling question: Would diabetes be a side effect of a cancer chemotherapy directed at inhibiting p110α? The study by Foukas et al. (2006) suggests that the answer is no. Although adult mice with attenuated p110α activity displayed all of the hallmarks of impaired insulin signaling, they did not progress to diabetes.
The term "off-target activity" bears a negative connotation. However, it is becoming increasingly apparent that some off-target activities can be beneficial and, in many cases, may be preferable to no offtarget activity at all. PI-103 blocks cancer cell growth by targeting two kinases. It is likely that many "drugs of the future" will exploit synergisms between two or more targets, and, as complex biological relationships among members of enzyme families are uncovered, parallel or synthetic interactions may identify efficacious target combinations. The two recent studies using small molecule inhibitors of the PI3-K family demonstrate that, even with imperfect tools, a detailed and accurate understanding of a complex biological system and target validation can be obtained.
